This website uses cookies, which are necessary for you to login to the My ICCA section, integrate social media and track visits to our website. ICCA is legally obliged to ask your permission to use cookies and to inform you about how we use them. By continuing to use our website you are accepting our use of cookies as described in our Privacy Policy. Find Out MoreContinue
Remember Associations only: Forgot password

GSK rethinks incentive programmes after Chinese bribery scandal

Share on LinkedIn

Pharma giant GlaxoSmithKline (GSK) has been fined almost £300 million after a Chinese court found it guilty of bribery.
The penalty, a £297m (3 billion RMB) fine, follows allegations that the drug company’s Chinese operation GSK China Investment Co (GSKCI) paid bribes to doctors and hospitals in order to have their products promoted.

To read the full article, please follow this link to the website of our media member Conference and Travel Publications Ltd.

More Knowledge Articles